Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
- Cancer
- Concussions
- CRISPR
- Drug Pricing
- End of Life
- Health Disparities
- Immigration
- Opioids
- Trump
- Women’s Health
- Zika
Multimedia
Popular
STAT Plus

Job Board
About

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

Cancer

First Opinion

Illness in doctors: a source of expertise, not a sign of weakness

By Erene Stergiopoulos

First Opinion

Who will pay for CRISPR?

By Jim Kozubek

advertisement

Pharmalot

FDA to study whether enough doctors understand claims in ads for cancer drugs

By Ed Silverman

advertisement

First Opinion

In defense of Medicare’s annual wellness exam

By Mara Schonberg

Health

New ethical lapses alleged in controversial India cervical cancer screening trial

By Charles Piller

First Opinion

Grappling with cancers that break all the rules

By David F. Arons

First Opinion

Landmark FDA approval bolsters personalized medicine

By Edward Abrahams

advertisement

In the Lab

Psst, the human genome was never completely sequenced. Some scientists say it should be

By Sharon Begley

advertisement

Pharmalot

Cancer patient sues Celgene for thwarting generic versions of its pricey meds

By Ed Silverman

First Opinion

Too much medical care: bad for you, bad for health care systems

By H. Gilbert Welch

Lab Chat

Scientists have created a ‘sunless tanner’ drug that boosts melanin in skin

By Megan Thielking

Health

New frontier in cancer care: Turning blood into living drugs

By Associated Press

Biotech

Personalized cancer therapies show great promise. The hitch? Manufacturing them efficiently

By Meghana Keshavan

Business

Saying Los Angeles lacks a great cancer center, Soon-Shiong plans to open one

By Rebecca Robbins

Biotech

Identifying another of cancer’s wily tricks: Masking pain so tumors can grow unnoticed

By Meghana Keshavan

Health

Study finds pregnancy seems safe for breast cancer survivors

By Associated Press

First Opinion

We need more data sharing to improve cancer treatment

By Thomas Brown and Jonathan C. Trent

Biotech

The winners and losers of #ASCO17

By Damian Garde

Health

A first: All respond to CAR-T therapy in a blood cancer study

By Associated Press

Health

Quickly reporting cancer complications may boost survival

By Associated Press

Biotech

U.S. could save $825 million a year with a small change in immunotherapy dosing, study says

Biotech

Meet the biotech company trying to shake up how the FDA thinks about cancer drugs

By Damian Garde

Biotech

Three key stories we’re watching for at ASCO

By Damian Garde

Health

At big cancer meeting, a big question: Is the U.S. ‘losing its edge’?

By Liz Szabo — Kaiser Health News

Health

Breast cancer survivors go fly-fishing for solace, healing

By Associated Press

First Opinion

The Affordable Care Act is still law. Signing up for health insurance is still hard

By Daniel Marchalik

Health

A taxpayer gamble on medical tourism: Louisiana subsidizes proton therapy to boost its economy

Pharmalot

Cancer docs favored drugs from companies who paid for meals and travel

By Ed Silverman

Pharmalot

Spending on cancer drugs is forecast to rise in the single digits

By Ed Silverman

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.

Sign up for our morning rounds newsletter

Reporting from the frontiers of health and medicine

About
Contact Us
The STAT Team
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT